Results 21 to 30 of about 15,084 (212)

SMARCA4/BRG1 protein-deficient thoracic tumors dictate re-examination of small biopsy reporting in non–small cell lung cancer [PDF]

Journal of Pathology and Translational Medicine, 2021
Background SMARCA4/BRG1 protein–deficient lung adenocarcinomas and thoracic sarcoma are recently described entities that lack distinctive histological features, transcription termination factor 1 (TTF1) reactivity, and actionable driver mutations.
Anurag Mehta, Divya Bansal, Rupal Tripathi, Ankush Jajodia   +3 more
doaj   +1 more source

[Clinical Characteristics and Prognosis Analysis of Thoracic SMARCA4-deficient
Undifferentiated Tumor versus SMARCA4-deficient Non-small Cell Lung Cancer]. [PDF]

Zhongguo Fei Ai Za Zhi
Background and objective Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a newly defined type of epithelial tumor in the 2021 World Health Organization (WHO) fifth edition classification of thoracic tumors, with a low incidence ...
Guo Y, Yang J, Lv X, Liu X, Li F, Wang J, Zhang P, Li J, Wang W.   +8 more
europepmc   +2 more sources

SMARCA4 regulates SMARCAD1 expression for toleration of replication stress in non-small cell lung cancer. [PDF]

Fujita Med J
Objectives: SMARCA4, a core component of the SWI/SNF chromatin remodeling complex, is frequently mutated in non-small cell lung cancer (NSCLC). SMARCA4-deficient cancer cells are associated with increased replication stress, one of the major causes of ...
Sawangsri P, Limsirichaikul S, Takeuchi T, Mizutani Y, Tran DQ, Kajino T, Suzuki M, Niimi A.   +7 more
europepmc   +2 more sources

Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study

Case Reports in Oncology, 2021
SMARCA4-deficient thoracic sarcoma is a newly described entity of thoracic sarcomas with a poor prognosis, defined by poorly differentiated epithelioid to rhabdoid histomorphology and SMARCA4 gene inactivation.
Nina Anžič, Fatime Krasniqi, Anna-Lena Eberhardt, Alexandar Tzankov, Jasmin Dionne Haslbauer   +4 more
doaj   +1 more source

SMARCA4-Deficient Undifferentiated Thoracic Tumor: Clinical Features and Prognosis of a Case Series and Literature Review. [PDF]

Clin Respir J
Introduction Thoracic SMARCA4‐deficient undifferentiated tumors (SMARCA4‐UT) are rare and aggressive epithelioid neoplasms characterized by the loss of the SMARCA4 gene.
Shan F, Liang S, Zhang Y, Wu W, Yang G, Yan M, Zhang X, Miao Y, Liu L, Cai J, Shi Z, Liu B, Zhang N.   +12 more
europepmc   +2 more sources

SWI/SNF regulates a transcriptional programme that induces senescence to prevent liver cancer [PDF]

, 2016
Oncogene-induced senescence (OIS) is a potent tumour suppressor mechanism. To identify senescence regulators relevant to cancer, we screened an shRNA library targeting genes deleted in hepatocellular carcinoma (HCC).
Banito, A, Carroll, T, Deswal, S, Garcia-Escudero, R, Ghamarlingam, G, Gil, J, Gonzalez Meljem, JM, Hohmeyer, A, Khan, S, Klotz, S, Martin, N, Martinez-Barbero, JP, Pedro, J, Raguz, S, Tordella, L, Zender, L, Zuber, J   +16 more
core   +2 more sources

Transcriptomic profiling of tumor-infiltrating CD4 + TIM-3 + T Cells reveals their suppressive, exhausted, and metastatic characteristics in colorectal cancer patients [PDF]

, 2020
T cell immunoglobulin mucin-3 (TIM-3) is an immune checkpoint identified as one of the key players in regulating T-cell responses. Studies have shown that TIM-3 is upregulated in the tumor microenvironment (TME).
Abu Nada, M, Ahmed, AA, Alajez, NM, Elkord, E, Kurer, MA, Murshed, K, Ouararhni, K, Sasidharan Nair, V, Soofi, ME, Taha, RZ, Toor, SM   +10 more
core   +2 more sources

Analysis of Clinicopathologic Features of 9 Cases of 
SMARCA4-deficient Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2022
Background and objective SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) is a rare primary lung malignancy. These diseases are not listed separately in the 2021 World Health Organization (WHO) classification of lung neoplasms, but they have
Runan ZHAO, Yitan ZOU, Hongyuan CHEN, Yanhua CHEN, Yanfang LIU, Miaoxia HE   +5 more
doaj   +1 more source

Tumor-agnostic therapy: a potential therapeutic approach for SMARCA4-deficient malignancies. [PDF]

Ther Adv Med Oncol
SMARCA4 deficiency plays a critical role in the oncogenesis of various aggressive tumors that exhibit resistance to conventional chemotherapy and radiotherapy, posing significant challenges to clinical management.
Liu Y, Liu ZH, Zhang Q, Bai YM, Guo XB, Ji HC, Zhang HM.   +6 more
europepmc   +2 more sources

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design [PDF]

, 2019
Targeting subunits of BAF/PBAF chromatin remodeling complexes has been proposed as an approach to exploit cancer vulnerabilities. Here, we develop proteolysis targeting chimera (PROTAC) degraders of the BAF ATPase subunits SMARCA2 and SMARCA4 using a ...
Arnhof, Heribert, Bader, Gerd, Boehmelt, Guido, Ciulli, Alessio, Dank, Christian, Diers, Emelyne, Ehrenhöfer-Wölfer, Katharina, Ettmayer, Peter, Farnaby, William, Galant, Michael, Gerstberger, Thomas, Gmaschitz, Teresa, Greb, Peter, Karolyi-Oezguer, Jale, Koegl, Manfred, McConnell, Darryl B., Owen-Hughes, Tom, Pearson, Mark, Petermann, Oliver, Riedmueller, Carina, Rinnenthal, Joerg, Roy, Michael J., Rumpel, Klaus, Schnitzer, Renate, Sharps, Bernadette, Steurer, Steffen, Trainor, Nicole, Traxler, Elisabeth, Wachter, Johannes, Weinstabl, Harald, Weiss-Puxbaum, Alexander, Whitworth, Claire, Wiechens, Nicola, Wu, Meng-Ying, Wöhrle, Simon, Zoephel, Andreas, Zollman, David   +36 more
core   +2 more sources